Supernus ADHD drug is FDA approved; first new ‘non-stimulant’ med in a decade

Attention-deficit hyperactivity disorder (ADHD) can be addressed by several medicines already commercially available but there’s now another treatment option and it’s the first new FDA-approved drug of its type in more than a decade. The FDA late Friday approved Supernus Pharmaceuticals’ drug viloxazine for the treatment of ADHD patients 6 to 17 years of age. The Rockville, Maryland-based company will market the once-daily, extended-release capsule under the name “Qelbree.”
Read more...

;